# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Higuchi Ichiyō (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI029-SYN-TD
- Date: 1896-06-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Aiko Lindgren-Tanaka, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

End of the eight-week intensive phase. **S**

## History of present illness

Ms. Higuchi returns at the end of the intensive phase, having taken all 56 doses by video, the last pyrazinamide dose yesterday. The isolate was susceptible to isoniazid, rifampin, pyrazinamide and ethambutol, and ethambutol was stopped by phone three weeks ago when the result arrived. The two-week sputum showed no acid-fast bacilli, and its culture has had no growth. The cough has gone and the night sweats stopped a month ago. She has no nausea, yellowing, dark urine, abdominal pain, numbness, or change in vision. She is eating well and has gained 2.5 kg. She is writing two hours each morning and has sent a story to an editor. **S**

| Element | Detail |
|---|---|
| Treatment | 56 of 56 intensive-phase doses observed; ethambutol stopped three weeks ago |
| Susceptibility | Susceptible to all four first-line drugs |
| Symptoms | No cough or night sweats |
| Weight | 41.0 kg, up 2.5 kg |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough or sputum; not breathless |
| Constitutional | Negative | No fever or night sweats; energy better |
| Gastrointestinal | Negative | No nausea, abdominal pain or jaundice |
| Eyes | Negative | No change in vision or colors |
| Psychiatric | Negative | Mood better; PHQ-9 5 |

5 systems reviewed. **S**

## Current medications

- Isoniazid 100 mg tablets, two tablets (200 mg) daily **S**
- Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 102/64 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 41 kg; BMI 18.7 kg/m². All vital signs are synthetic.

ALT: 26 U/L; AST: 25 U/L; Total bilirubin: 0.5 mg/dL; Albumin: 3.8 g/dL; Hemoglobin: 12.4 g/dL; Visual acuity, right eye (ETDRS letters): 85; Visual acuity, left eye (ETDRS letters): 85; PHQ-9: 5. All results are synthetic.

## Change since baseline

- ALT: 12 U/L at baseline, 26 U/L at this visit **S**
- AST: 19 U/L at baseline, 25 U/L at this visit **S**
- Total bilirubin: 0.4 mg/dL at baseline, 0.5 mg/dL at this visit **S**
- Albumin: 3.3 g/dL (low) at baseline, 3.8 g/dL at this visit **S**
- Hemoglobin: 11.4 g/dL (low) at baseline, 12.4 g/dL at this visit **S**
- Visual acuity, right eye (ETDRS letters): 85 at baseline, 85 at this visit **S**
- Visual acuity, left eye (ETDRS letters): 85 at baseline, 85 at this visit **S**
- PHQ-9: 8 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Looks well; weight 41.0 kg, BMI 18.7; temperature 36.8 °C, pulse 80 |
| Eyes | No icterus. Visual acuity 85 letters in each eye; Ishihara plates normal |
| Respiratory | Clear on both sides |
| Abdomen | Soft and non-tender |
| Neurological | Normal sensation in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pulmonary tuberculosis, drug-susceptible, end of the intensive phase** (A15.0). Excellent clinical response with full adherence. ALT 26, AST 25, bilirubin 0.5, all normal. Without a cavity on the first X-ray, the continuation phase is four months. If the two-month culture were positive, extension to seven months would be considered because she is underweight; it is not changed while that culture is pending. **S**
   - Isoniazid 200 mg, rifampin 450 mg and pyridoxine 50 mg daily by video-observed therapy for eighteen weeks from today.
   - Pyrazinamide finished yesterday.
   - Induced sputum today for the two-month smear and culture.
   - In the continuation phase, liver tests only for symptoms, since the tests stayed normal and albumin has recovered; the observing nurse asks about symptoms at each dose.
2. **Moderate protein-calorie malnutrition, improving** (E44.0). Weight 41.0 kg and albumin 3.8 g/dL; hemoglobin 12.4 g/dL, up from 11.4 as the infection settles. **S**
   - Continue the meal plan and supplement drinks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, fever, night sweats | At least monthly during treatment | Completed today | No cough, fever or night sweats |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 41.0 kg, up 2.5 kg; albumin 3.8 g/dL; doses unchanged |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | No symptoms |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Completed today | ALT 26, AST 25 U/L, bilirubin 0.5 mg/dL, all normal |
| Laboratory | Monthly liver tests in the intensive phase (month one) | Monthly in the intensive phase because of low weight and albumin | Deferred | Missed: the liver tests due about four weeks into treatment were not drawn, because no visit was booked and the phone call that stopped ethambutol did not include a blood test. No harm judging by today's normal results and the absence of symptoms at every observed dose. Corrective action: blood tests due between visits are now booked as laboratory visits with a reminder to the observing nurse |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Deferred | Missed: the monthly vision check due about four weeks into treatment, while she was still taking ethambutol, was not done for the same reason. No harm: acuity 85 letters in each eye and normal color vision today, three weeks after ethambutol was stopped. Corrective action: any future ethambutol course is booked with monthly vision checks |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Completed today | Susceptible to isoniazid, rifampin, pyrazinamide and ethambutol; ethambutol stopped three weeks ago |
| Laboratory | Two-month sputum smear and culture | At the end of the intensive phase | Completed today | Two-week specimen smear-negative with no growth so far; two-month induced specimen sent today |
| Laboratory | Blood count | At diagnosis, then as needed | Completed today | Hemoglobin 12.4 g/dL, up from 11.4 |
| Medication safety | Continuation-phase length | At the end of the intensive phase | Completed today | Four months planned, because there was no cavity; extension to seven months would be considered if the two-month culture were positive, because she is underweight |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | 56 of 56 doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine continues |
| Medication safety | Rifampin drug-interaction review, including hormonal contraception | With every new medicine | Completed today | No new medicines |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Referred | Continuing with the public health center; results not part of her record |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | PHQ-9 5, from 8; item 9 scored 0 |

## Goal progress

- Complete 182 daily doses within about six and a half months by video-observed therapy. In progress; target 1896-10-20. **S**
- Sputum culture negative at two months. In progress; target 1896-10-20. **S**
- Weight at least 44 kg (BMI about 20) by the end of treatment. In progress; target 1896-10-20. **S**
- Keep writing on a paced schedule without losing income during treatment. In progress; target 1896-10-20. **S**
- No drug-induced liver injury or loss of vision during treatment. In progress; target 1896-10-20. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases 2016;63(7):e147-e195)
- Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025), American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America (American Journal of Respiratory and Critical Care Medicine 2025;211(1):15-33)
- WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022), World Health Organization
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017), American Thoracic Society, Infectious Diseases Society of America, and Centers for Disease Control and Prevention (Clinical Infectious Diseases)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current), Ministry of Health, Labour and Welfare, Japan
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Two-month culture result by phone. Preventive visit as booked. End-of-treatment visit after the 182nd dose. Call for cough, fever, weight loss, hepatitis symptoms or numbness. **S**
- Next scheduled visit 1896-08-24: periodic adult preventive visit. **S**
